Home Latest Articles
Latest Articles
  • Wencai YANG, Peiyao ZHOU, Daqi LI
    World Clinical Drug. 2022, 43(9): 1188-1192.
  • Zongbiao ZHAO, Na YIN, Yan ZHANG, Bingxiang SHEN, Lixia LI
    World Clinical Drug. 2022, 43(9): 1193-1198.
  • Shuyun SHEN
    World Clinical Drug. 2022, 43(9): 1199-1206.

    Glucagon-like peptide-1 receptor agonist (GLP-1 RA) is a new class of hypoglycemic drugs, which is increasingly important in the treatment of type 2 diabetes mellitus (T2DM) due to its outstanding effects of hypoglycemia, weight loss and low risk of hypoglycemia. Over the past several years, the developer has completed seven cardiovascular outcome trial (CVOT) involving liraglutide, once-weekly long-acting exenatide, lixisenatide, abirlutide, duraglutide, semaglutide as a subcutaneous injection, and semaglutide as an oral formulation. The cardiovascular outcomes of all GLP-1 RAs were found to be noninferior to placebo, and some GLP-1 RAs were found to be superior. The results of these trials have changed national guidelines for medical treatment of T2DM. This article reviewed 7 CVOTs of GLP-1 RAs, in order to provide more support for clinical medication.

  • Yiran CHEN, Bin FAN
    World Clinical Drug. 2022, 43(9): 1207-1213.

    Psoriasis is a chronic inflammatory skin disease, with erythema, scales as the main clinical manifestations, long course of disease, lingering difficult to recover. Curcumin, a phenolic substance extracted from the traditional Chinese medicine Rhizoma Curcumae Longae, which has anti-inflammatory, antioxidant and anti-tumor effects, and has certain therapeutic effects on psoriasis. Due to the limitations of curcumin such as low oral administration availability and poor permeability of traditional topical administration, in order to improve the utilization rate of curcumin and expand its application in chronic skin diseases such as psoriasis, the studies of curcumin local delivery system have become a hot topic. This paper mainly reviewed the mechanism of curcumin in the treatment of psoriasis and summarized the research progress on the local drug delivery system of curcumin, so as to provide reference for further research on curcumin.

  • Ge GAO, Haiyang QIAN, Linya LIU, Jiuhong WU
    World Clinical Drug. 2022, 43(9): 1214-1221.

    This paper introduced the definition of adherence (including medication, exercise, diet, and etc.), and illustrates the loss from non-adherence and the gains from improved adherence by taking diabetes mellitus and hypertension as examples. Based on the analysis of previous literature, this paper summarized some main experiences and lessons, and identifies five major factors influencing adherence: social and economic, health care system, therapy-related factor, condition-related factor and patient-related factor. Based on the roles of medical institutions, medical staff, pharmaceutical companies and payers, this paper discussed how to play their own advantages in their respective areas to better integrate multidisciplinary practices and coordinate actions to improve adherence. It also called on experts, academics and industry institutions to actively develop relevant standards for adherence management, regulate medical practices, and enhance the value of treatment and patient outcomes.

  • Xiaochen WU, Shan HE, Jun LU
    World Clinical Drug. 2022, 43(8): 961-966.

    T-cell malignant tumors are characterized by high malignancy and poor prognosis. Hematopoietic stem cell transplantation is the most effective treatment approach in relapsed or refractory T-cell malignancies, which is often accompanied by severe transplantation-associated complications. Therefore, it is urgent to explore safe and effective therapies. Chimeric antigen receptor T cell therapy (CAR-T cell therapy), as a relatively novel immunotherapy method, has achieved great clinical benefits in relapsed or refractory B cell malignant tumor and multiple myeloma. Up to now, eight related drugs have been approved (6 approved by FDA and 8 approved by CFDA). However, for T-cell malignant tumors, CAR-T cell immunotherapy is still in the stages of preclinical and (or) early clinical, and faces many difficulties and challenges. This article reviewed the current research progress of CAR-T cell therapy for T cell malignancies.

  • Xiaojun YUAN
    World Clinical Drug. 2022, 43(8): 967-974.

    The prognosis of pediatric neuroblastoma (NB) is highly heterogeneous, the long-term survival rate of high-risk or recurrent or refractory NB patients remains less than 50%. Disialoganglioside (GD2) is highly expressed in NB cells, but limited expression in normal tissues. Therefore, GD2 monoclonal antibody (mAb) therapy has become a specific immunotherapy for high-risk and recurrent or refractory NB patients. GD2 mAb binds to GD2 antigen to form immune complex, which plays antitumor effects by inducing antibody-dependent and complement-dependent immune mechanisms. GD2 mAb can significantly improve the survival rate of high-risk and recurrent or refractory NB patients, but attention should be paid to the management of adverse reactions in different groups during treatment. The timing of GD2 mAb combined with chemotherapy, as well as the benefits and risks combined with immune checkpoint inhibitors programmed cell death protein-1/programmed cell death 1 ligand-1, iodine-131-labeled metaiiodo-benzylguanidine or chimeric antigen receptor T cells should be explored. This article reviewed the research progress of GD2 mAb in the treatment of high-risk or recurrent or refractory NB in children in recent years, in order to provide some reference for clinical treatment.

  • Xiaohong QIAO
    World Clinical Drug. 2022, 43(8): 975-981.

    Programmed cell death protein-1 (PD-1)/programmed cell death 1 ligand-1 (PD-L1) inhibitors have certain antitumor activity on children with recurrent or refractory Hodgkin lymphoma (HL), recurrent or refractory primary mediastinal large B-cell lymphoma, unresectable or metastatic microsatellite instability-high or deficient mismatch repair solid tumor with progression after treatment, recurrent or metastatic Merkel cell carcinoma, especially in children with recurrent or refractory HL. Insufficient expression of PD-1 and PD-L1 can be used as biomarkers to select children who may respond to PD-1/PD-L1 inhibitors. Cytotoxic T lymphocyte antigen-4 inhibitors can be used for the treatment of patients aged 12 and over with unresectable tumors and metastatic melanoma. Immune checkpoint inhibitors (ICIs) are relatively safe and well tolerated. The combined application of multiple ICIs, combined with chemotherapeutic drugs, DNA methyltransferase inhibitors, CD30 antibodies and chimeric antigen receptor T-cell immunotherapy may further improve the curative effect. This article reviewed the research progress of ICIs in the treatment of pediatric hematologic malignancies and tumors in recent years, in order to provide some reference for clinical diagnosis and treatment.

  • Jiuhong WU, Yifeng CHAI, Wannian LIANG
    World Clinical Drug. 2022, 43(8): 982-985.

    In this paper, the definition of pharmaceutical security and drug supply in public emergencies and their respective focus directions are sorted out, and the key point is to discuss the construction of macro pharmaceutical security system and the implementation of micro pharmaceutical supply practice technology under emergencies. The construction of the drug emergency system is an important part and material support of the whole health emergency system, which plays a direct and crucial role in the overall effectiveness of the medical and health emergency work. The article also gives in-depth thinking and corresponding suggestions on improving the efficiency and level of the construction of the emergency support system in the future, gives priority to the construction of the medical and health emergency system, and gives guidance and suggestions on continuous promotion and improvement in command and decision-making, rapid disposal, priority support and capacity building for the sake of people's health and safety.

  • Pingping SUN, Kaiwen HUANG, Jiuhong WU, Shuxia LI
    World Clinical Drug. 2022, 43(8): 986-992.

    It is a difficult for the management of special clinical drugs in public health emergencies to push potential and effective drugs to the clinical front line in time and use them widely and reasonably. This article comprehensively combs the relevant policies and regulations of China for the application management of off-label application of marketed drugs and the accelerated approval of unlisted drugs in the clinical application in public health emergencies, provides reference for the clinical application management of relevant special drugs in public health emergencies, and provides ideas and methods for the strategic development of drugs in response to public health emergencies.

News